David Lynch
Neurology with Special Qualifications in Child Neurology · Philadelphia, PANPI 1578597209
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.8%), education and travel and lodging — rather than concentrated in one kind of arrangement. Biogen accounts for 60.3% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $9,704, more than ten times the $894 reported in 2019.
Across 18 payments — averaging $882.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$10K
- Biomarin Pharmaceutical Inc.$3K
- Intuitive Surgical$2K
- Takeda Pharmaceuticals U.S.A., Inc.$894
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$500
- PTC Therapeutics, Inc.$128
Across 346 payments — averaging $10,853 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- PTC Therapeutics, Inc.$2.3M
- Biogen$1.4M
- Takeda Pharmaceuticals U.S.A., Inc.$41K
- United Therapeutics Corporation$13K
What the payments were for
- Consulting fees$8,22052%
- Speaking & faculty fees$8946%
- Travel & lodging$2,99419%
- Food & beverage$4433%
- Education$3,33321%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 10 | $9,576 |
| Biomarin Pharmaceutical Inc. | 1 | $2,833 |
| Intuitive Surgical | 3 | $1,952 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $894 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 1 | $500 |
| PTC Therapeutics, Inc. | 1 | $128 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,933
- Skyclarys$1,109
How this compares
$15,884 in reported general payments places this provider in the 85th percentile of 83 neurology with special qualifications in child neurology providers in Pennsylvania.
See all neurology with special qualifications in child neurology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SkyclarysOmaveloxolone | 337 | $9,982,638 |
| Baclofen | 128 | $3,585 |
| Levocarnitine | 15 | $2,450 |
| AmantadineAmantadine Hcl | 47 | $1,743 |
| Gabapentin | 82 | $1,716 |
| Oxybutynin Chloride ErOxybutynin Chloride | 13 | $629 |
| Riluzole | 13 | $453 |
| Tizanidine Hcl | 12 | $322 |
| Citalopram HbrCitalopram Hydrobromide | 32 | $271 |
| Levetiracetam | 19 | $269 |
| Clonazepam | 11 | $268 |
| Divalproex Sodium | 12 | $129 |
| Primidone | 13 | $114 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenSkyclarys | $9,576 | $9,982,638337 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 83 neurology with special qualifications in child neurology providers in Pennsylvania.
Other neurology with special qualifications in child neurology in Philadelphia
- John BrandsemaPhiladelphia$526K
- Susan MatesanzPhiladelphia$138K
- Elizabeth KichulaPhiladelphia$90K
- Dennis DlugosPhiladelphia$88K
- Alexandra KornbluhPhiladelphia$88K
- Nicholas AbendPhiladelphia$56K
- Sabrina YumPhiladelphia$33K
- Eric MarshPhiladelphia$28K
- Christina SzperkaPhiladelphia$18K
- Marissa DigiovinePhiladelphia$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.